Diabetes Care recently published online before print full results from a phase 2 trial of Mesoblast’s mesenchymal precursor cell (MPC) treatment for type 2 diabetes aimed at reducing inflammation. Topline results were released at the end of 2013. The multicenter 12-week, single-blind, dose escalation trial randomized 61 type 2 diabetes patients (mean A1c of 8.3% and diabetes duration of 10 years) to receive a single intravenous infusion of 0.3, 1.0, or 2.0 million MPCs/kg or placebo. After 12 weeks, the MPC treatment produced modest, dose-dependent A1c reductions compared to placebo (0.0%, -0.1%, and -0.3% respectively for the 0.3, 1.0, and 2.0 million MPCs/kg doses). The greatest difference in A1c was seen in the highest dose group at week eight with a 0.4% reduction vs. placebo (P<0.05). At 12 weeks, five (33.3%) subjects in the highest dose group had achieved the <7% A1c target compared to none in the placebo group (P<0.05). As is commonly seen, the treatment seemed to demonstrate greater efficacy in patients with starting A1c ≥8% – a 0.4% reduction in the highest dose group compared to a 0.2% reduction in patients with a starting A1c <8%. There was no observed difference in fasting glucose levels, suggesting this treatment may be targeting postprandial effects. Crucially, the study saw no serious adverse events, serious hypoglycemia, or discontinuations over the 12-week trial period, meeting its primary endpoint. In addition, no immune responses against MPC donor antigens were identified in any subject. We are glad to see these reassuring safety results and look forward to seeing efficacy results from more robust trials in the future. Stem cell treatments are a hot topic in diabetes treatment right now, though most therapies in the pipeline are focused on type 1 diabetes (see Melton group and ViaCyte). Mesoblast is also currently in phase 2 trials investigating MPCs as a diabetic nephropathy treatment.
Testimonials Read More
I feel very comfortable referring my clients to Arlene Howard PR as she gets results and always delivers what she promises.

As CEO of Aier-USA, part of the world’s largest eye group servicing 3 billion people worldwide, Arlene Howard has played a critically important role in our growth! I have worked with Arlene and her company since 2017, and although I had previously worked with many public relations firms, I can confidently say that our experience with Arlene and her organization has far surpassed any of them. Arlene and her team care deeply about their clients, customize their work based on the specific needs of each client, and work extremely hard to follow through on each task and make the interests of their clients a top priority. The most impressive aspect of Arlene and her team’s work is the RESULTS. They have produced some of the best PR results for us that we have ever experienced, including the production of a major article about Aier-USA in Forbes Magazine, articles in USA Today and EyeWorld, the authoritative magazine of our profession, and prominent TV appearances such as the one on Daystar, one of the country’s top Christian TV networks. If you are looking for the best, one-stop-shop company that truly cares for your business’ success, who will go the extra mile to make things happen for you, can produce prominent national PR exposures, and is totally dedicated to providing results to help your company move into the highest level of business success, Arlene Howard Public Relations should be your #1 choice!
We hired Arlene and her team to publicize our Peel and skin care line in 2016 after interviewing several other companies.
We found Arlene and her entire team to be hardworking, responsive and genuinely excited about our product.
They quickly understood our product, our PR targets and how to get our product out there to TV, print and online media. Arlene got us on several national TV shows within a short time period.
I recommend AHPR without hesitation if you want an established, hardworking and well connected team of professional to publicize your product or service.